Covered recipient · General Payments record
WALTER MATTHEW PORTER
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$3,099.10
- Reported across 175 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $335.96 | 13 |
| Education | $199.98 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $144.89 | 3 |
| ABBVIE INC. | $115.80 | 2 |
| Daiichi Sankyo Inc. | $63.38 | 1 |
| Astellas Pharma US Inc | $44.61 | 2 |
| AVEO Pharmaceuticals, Inc. | $44.27 | 1 |
| Regeneron Healthcare Solutions, Inc. | $32.53 | 1 |
| TerSera Therapeutics LLC | $21.50 | 1 |
| EISAI INC. | $17.80 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.49 | 1 |
| GENZYME CORPORATION | $16.87 | 1 |
| Genmab U.S., Inc. | $16.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.81 | 06/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108032121 | CMS |
| ABBVIE INC. | $99.99 | 08/08/2024 | Education | Undisputed | 01/23/2026 | 1108032123 | CMS |
| Astellas Pharma US Inc | $23.57 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139471300 | CMS |
| Astellas Pharma US Inc | $21.04 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139552457 | CMS |
| Aveo Pharmaceuticals, Inc. | $44.27 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143500015 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $17.49 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086350721 | CMS |
| Daiichi Sankyo Inc. | $63.38 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089470333 | CMS |
| Eisai Inc. | $17.80 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110825008 | CMS |
| Genmab U.S., Inc. | $16.80 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126839646 | CMS |
| GENZYME CORPORATION | $16.87 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139938259 | CMS |
| Incyte Corporation | $24.45 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141209079 | CMS |
| Incyte Corporation | $99.99 | 06/28/2024 | Education | Undisputed | 01/23/2026 | 1141206959 | CMS |
| Incyte Corporation | $20.45 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141178718 | CMS |
| Regeneron Healthcare Solutions, Inc. | $32.53 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114358248 | CMS |
| TerSera Therapeutics LLC | $21.50 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144724204 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.